Matches 1 - 50 out of 275 1 2 3 4 5 6 >


Match Document Document Title
US20110002989 METHODS, DOSAGE FORMS AND KITS FOR ADMINISTERING ZIPRASIDONE WITHOUT FOOD  
The present invention provides methods, dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment,...
US20130131063 Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners  
The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with...
US20150119383 ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME  
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other...
US20130245004 ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME  
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other...
US20130143867 ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME  
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other...
US20130090329 Methods and Compositions for the Treatment of Psychotic Disorders Through the Identification of the Olanzapine Poor Response Predictor Genetic Signature  
Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a OPRP genetic...
US20130143885 CHEMICAL INDUCERS OF NEUROGENESIS  
The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The methods may take place in vitro, such as...
US20120277211 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS THROUGH THE IDENTIFICATION OF THE SULT4A1-1 HAPLOTYPE  
Methods and compositions that relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1...
US20110105467 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS THROUGH THE IDENTIFICATION OF THE SULT4A1-1 HAPLOTYPE  
Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1...
US20140234443 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF  
Novel 5-HT3 receptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and...
US20120219641 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF  
Novel 5-HT3 receptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and...
US20150031677 TRIOXANE THIOACETAL MONOMERS AND DIMERS AND METHODS OF USE THEREOF  
Monomeric and dimeric trioxane thioacetals and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic...
US20140349999 METHODS FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN  
The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present...
US20120077800 Methods for Treating Antipsychotic-Induced Weight Gain  
The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present...
US20110152272 Treatment Of Incontinence  
The present invention relates to the use of agonists of 5-HT2C receptors for the treatment of urinary incontinence, preferably mixed incontinence or stress urinary incontinence. The invention also...
US20140018348 Composition and Method for Treatment of Depression and Psychosis in Humans  
Compositions and methods tor the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or...
US20140206667 METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA  
The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and...
US20110237602 METHOD FOR TREATING SCHIZOPHRENIA AND RELATED DISEASES  
The invention relates to a method for treating schizophrenia and/or related diseases comprising administering lurasidone and a mGluR2 ligand to a mammal in need thereof.
US20140350000 Genetic Markers for Optimizing Treatment for Schizophrenia  
This document provides methods and materials related to genetic markers for predicting response to a treatment for schizophrenia (SZ). For example, methods for using such genetic markers to select...
US20100310681 Modulation of KCNQ Potassium Channel Activity for Treatment of Psychiatric Disorders and the Symptoms Thereof  
Disclosed herein are compositions and methods for treating a psychiatric disorder or symptoms thereof in a patient. The compositions comprise a compound that modulates KCNQ (Kv7) potassium channel...
US20130053341 THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE  
Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP) are de-scribed herein. Exemplary disorders include schizophrenia and cognitive deficit.
US20120091022 SUSTAINED-RELEASE FORMULATION FOR INJECTION  
The present invention relates to a composition comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3 -tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]h eptanedicarboximi...
US20130172365 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES  
Arylsulphonamide derivatives of formula (I) and pharmaceutically acceptable salts thereof. The compounds may be useful for the treatment and/or prevention of disorders of the central nervous system.
US20140350029 LURASIDONE NOVEL DOSAGE REGIMENS AND USE THEREOF FOR THE TREATMENT, PREVENTION, AND/OR MANAGEMENT OF AT LEAST ONE CNS DISORDER  
Dosage regimens for at least one compound chosen from Iurasidone and pharmaceutically acceptable salts, solvates, clathrates, and stereoisomers thereof are disclosed as are kits and methods for...
US20130018056 METHOD OF TREATMENT FOR MENTAL DISORDERS  
The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D4 receptor agonist.
US20120115879 METHOD OF TREATMENT FOR MENTAL DISORDERS  
The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D4 receptor agonist.
US20110166156 Prodrugs for the Treatment of Schizophrenia and Bipolar Disease  
Compounds of Formula I and Formula II and their use for the treatment of neurological and psychiatric disorders including schizophrenia and manic or mixed episodes associated with bipolar I...
US20140113912 TREATMENT AND MANAGEMENT OF CNS DISORDERS  
The present disclosure relates to methods of treating certain CNS disorders. The present disclosure also relates to biomarkers for monitoring or predicting the efficacy of a treatment for a CNS...
US20140024638 TREATMENT OF COGNITIVE DYSFUNCTION IN SCHIZOPHRENIA  
The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3- yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof, pharmaceutical...
US20150231126 COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS  
Combinations of 5-HT2A inverse agonists or antagonists such as pimavanserin with antipsychotics such as risperidone are shown induce a rapid onset of antipsychotic action and increase the...
US20140288054 GENETIC MARKERS OF MENTAL ILLNESS  
This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ), and methods of use thereof.
US20130196996 USE OF ISOXAZOLINE COMPOUNDS AND COMPOSITIONS IN BLADDER CANCER  
One embodiment provides a method, comprising treating or preventing at least one disease selected from the group consisting of bladder cancer, weight loss accompanying bladder cancer, bone pain...
US20120077802 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF  
Provided herein are spiro-cyclic compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various...
US20110269768 UROTENSIN II RECEPTOR ANTAGONISTS  
This invention is directed to a compound of Formula (I): and forms thereof, wherein A, B, E, G, X and L2 are as defined herein and their use as urotensin II receptor antagonists.
US20120142701 COMPOUNDS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES  
Cell-based and cell-free assays are disclosed that detect compounds that promote aggregation of proteins, glycoproteins, and protein-nucleic acid complexes. Also disclosed are pharmaceutical...
US20140371236 AGENT FOR TREATMENT OF SCHIZOPHRENIA  
The present invention provides a novel method for treatment of schizophrenia which can improve wide-ranging symptoms of schizophrenia, especially positive symptoms and negative symptoms without...
US20150246056 METHODS FOR TREATING OR PREVENTING SYMPTOMS OF HORMONAL VARIATIONS  
A method for treating or preventing symptoms of hormonal variation includes administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal...
US20130281436 DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA  
The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous...
US20140194409 Method of administration of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia  
The present invention relates to 4-((1R,3S)-6-chloro-3-phenyl-indan-1yl)-1,2,2-trimethyl-pipe razine and the salts thereof with activity at dopamine D1 and D2 receptors as well as the serotonin...
US20120231092 Combination Therapy for Bipolar Disorder  
Treatment regimens for mood disorders that include administration of buprenorphine, alone or in combination with additional pharmacological agents are described. Specifically, treatment regimens...
US20130053372 5-HT RECEPTOR MODULATORS  
The invention relates to compounds of formula (I), useful for treating disorders mediated by the 5-hydroxytryptamine (serotonin) receptor IB (5-HT1B), e.g. vascular disorders, cancer and CNS...
US20130108701 Solid Dosage Forms of Antipsychotics  
The present invention relates to a solid dosage form comprising an antipsychotic, particularly ziprasidone. The present invention also relates to a process for preparation of solid dosage form...
US20100292211 ANTIPSYCHOTIC TREATMENT BASED ON SNP GENOTYPE  
The present invention relates to the prediction of antipsychotic treatment efficacy based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a...
US20150157628 Pharmaceutical compositions of Lurasidone and Process for preparation thereof  
Pharmaceutical compositions comprising an atypical antipsychotic as an active agent, process of preparation thereof and method of using the same are provided. Particularly the present invention...
US20110212975 ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THEREOF  
Compounds which exhibit antiviral activity, particularly against influenza virus, and methods of making and using thereof are described herein. In one embodiment, the compounds are heterocyclic...
US20100324044 METABOTROPIC GLUTAMATE RECEPTOR ISOXAZOLE LIGANDS AND THEIR USE AS POTENTIATORS  
Compounds in accord with Formula I: wherein R1, R2, R3 and R4 are as defined in the specification, pharmaceutically acceptable salts, methods of making, pharmaceutical compositions containing and...
US20100317662 Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286  
Compounds in accord with Formula I: wherein R1, R2, R3 and R4 are as defined in the specification, pharmaceutically acceptable salts, methods of making, pharmaceutical compositions containing and...
US20140228331 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS  
The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of...
US20110301133 COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS  
The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of...
US20120149715 COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS  
High throughput and virtual screening methods are disclosed that can identify potential anti-viral agents. The virtual screening methods identify agents that interact with a viral nucleoprotein...

Matches 1 - 50 out of 275 1 2 3 4 5 6 >